uniQure N.V. Faces Securities Fraud Class Action Following FDA Approval Setbacks and Significant Stock Plunge
On February 13, 2026, Kahn Swick & Foti, LLC (KSF) announced a significant ongoing class action lawsuit against uniQure N.V., driven primarily by allegations of securities fraud. The case centers around serious claims that uniQure did not adequately disclose essential information regarding its drug candidate, AMT-130, which was anticipated to receive expedited approval from the U.S. Food and Drug Administration (FDA). This approval was expected to follow uniQure's planned submission of a Biologics License Application (BLA) in the first quarter of 2026.
However, a critical development emerged on November 3, 2025, when investors were informed that the FDA raised doubts about whether the data from AMT-130’s Phase I/II studies could support the BLA submission. This revelation sent shockwaves through the market, resulting in uniQure's stock plummeting more than 49%, from $67.69 on October 31, 2025, to just $34.29 following the announcement. The drastic decline in the stock price exemplifies the serious repercussions that can arise from a failure to disclose material information, an aspect that has drawn the attentions of shareholders.
This class action is rooted in the securities that were purchased between September 24, 2025, and October 31, 2025, a period during which investors believed they were making informed decisions based on uniQure's optimistic projections. The lawsuit highlights the responsibility companies have to provide transparent and timely communication, particularly when it concerns information that could significantly impact their stock’s value.
For those who suffered substantial financial losses during this time frame, KSF is urging them to consider taking action before the April 13, 2026, deadline for filing lead plaintiff applications. Affected shareholders are encouraged to reach out to Lewis Kahn, Managing Partner at KSF, to explore their legal rights and the implications of the class action lawsuit. Kahn Swick & Foti, known for its specialization in securities litigation, strives to recover losses for investors linked to corporate misconduct. With offices across the U.S. and a reputation for high recovery settlements, KSF aims to stand up for individual investors who feel wronged in this situation.
In summary, the ongoing class action against uniQure N.V. serves as a crucial reminder of the intricate relationship between corporate communication and investor trust. The implications of this case could set significant precedents in the field of securities law, particularly with respect to the obligations of publicly traded companies to candidly inform their investors. As the hearing date approaches, all eyes will be on how this legal battle unfolds and the precedent it may set for future securities fraud cases.
However, a critical development emerged on November 3, 2025, when investors were informed that the FDA raised doubts about whether the data from AMT-130’s Phase I/II studies could support the BLA submission. This revelation sent shockwaves through the market, resulting in uniQure's stock plummeting more than 49%, from $67.69 on October 31, 2025, to just $34.29 following the announcement. The drastic decline in the stock price exemplifies the serious repercussions that can arise from a failure to disclose material information, an aspect that has drawn the attentions of shareholders.
This class action is rooted in the securities that were purchased between September 24, 2025, and October 31, 2025, a period during which investors believed they were making informed decisions based on uniQure's optimistic projections. The lawsuit highlights the responsibility companies have to provide transparent and timely communication, particularly when it concerns information that could significantly impact their stock’s value.
For those who suffered substantial financial losses during this time frame, KSF is urging them to consider taking action before the April 13, 2026, deadline for filing lead plaintiff applications. Affected shareholders are encouraged to reach out to Lewis Kahn, Managing Partner at KSF, to explore their legal rights and the implications of the class action lawsuit. Kahn Swick & Foti, known for its specialization in securities litigation, strives to recover losses for investors linked to corporate misconduct. With offices across the U.S. and a reputation for high recovery settlements, KSF aims to stand up for individual investors who feel wronged in this situation.
In summary, the ongoing class action against uniQure N.V. serves as a crucial reminder of the intricate relationship between corporate communication and investor trust. The implications of this case could set significant precedents in the field of securities law, particularly with respect to the obligations of publicly traded companies to candidly inform their investors. As the hearing date approaches, all eyes will be on how this legal battle unfolds and the precedent it may set for future securities fraud cases.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.